Specialty Pharmacy

From 1990 to 2016, the rate of deaths due to adverse effects of medical treatment decreased 21.4% in the United States.

Officials with the FDA today approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin.

Recommendations outline the efficacy of different types of therapies, dosing regimens, and routes for patients with mild-to-moderate ulcerative colitis.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Understanding the rate of hepatitis C infection is critical for making strategies to reduce the disease burden among specific populations.

Atezolizumab (Tecentriq) plus chemotherapy significantly extended survival in patients with metastatic non-squamous non-small cell lung cancer.

The target action date for the FDA’s decision on caplacizumab (Cablivi) is February 6, 2019.

Top news of the day across the health care landscape.

Ocrelizumab found more effective in reducing the risk of 12-week confirmed disability progression compared with 10 other treatments for relapsing multiple sclerosis.

Vigabatrin, which is also sold under the brand name Sabril, is used to treat complex partial seizures in adult and pediatric patients.

Zanubrutinib (BGB-3111) is being investigated for the treatment of various B-cell malignancies, including mantle cell lymphoma.

Offering screening and referrals for mental health and peer support services can improve HIV outcomes in American Indian and Alaska Native patients.

Top news of the day across the health care landscape.

The committee is seeking detailed information and documents about some pharmaceutical companies' prescription drug pricing practices.

Application of core area methodology can help identify new hepatitis C cases and outbreaks and improve testing and treatment.

With this technology interface, the health care system could experience enhanced communication, efficiency, and regulatory compliance, which makes patient safety the ultimate benefit.

Officials with CVS Health have announced that Walmart has opted to leave CVS Caremark pharmacy benefit management commercial and Managed Medicaid retail pharmacy networks.

Cabozantinib’s new indication provides an additional therapeutic option for patients with advanced liver cancer who have been previously treated with sorafenib.

Patients with low-risk prostate cancer that harbors certain genetic alterations may have a higher risk of disease progression.

Top news of the day across the health care landscape.

People who inject drugs may not accurately self-report HIV and antiretroviral drug status when entering an HIV prevention study.

Researchers identified an immune receptor that may lead to new drug treatments that target immune activation in patients with HIV.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, talks about how technology can enhance patient care from a pharmacy perspective.

Top news of the day across the health care landscape.

Trial comparing oral ponesimod versus teriflunomide (Aubagio) in relapsing multiple sclerosis will evaluate annualized relapse rate as well as other disease activity measures.

A newly-developed biomedical device may help prevent chemotherapy from spreading away from the targeted tumor.

Top news of the week from Specialty Pharmacy Times.

Top news of the day across the health care landscape.